SLGC SomaLogic Inc

SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the third quarter 2023 after market close on November 8, 2023. Management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived version of the webcast will be available at https://investors.somalogic.com/.   

About SomaLogicSomaLogic is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 7,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body and twice as many as other proteomic platforms. For more than 20 years we’ve supported pharmaceutical companies, and academic and contract research organizations who rely on our protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases. Find out more at www.somalogic.com and follow @somalogic on LinkedIn.

Investor ContactMarissa BychGilmartin Group LLCinvestors@somalogic.com

SomaLogic ContactEmilia Costales720-798-5054ecostales@somalogic.com